Alzheimer's disease: transgenic models to test new chemicals and pharmaceuticals.
Alzheimer's disease is the most common form of senile dementia and is predicted to become even more prevalent as the proportion of elderly in the population increases over the next few decades. As yet, there are no effective treatments for the disorder. A major limitation to identifying new drugs and therapeutic targets for Alzheimer's disease has been the absence of an animal model displaying typical Alzheimer's pathology. Transgenic technology is now providing a powerful new approach for the development of animal models of Alzheimer's disease.
Department of Neuroscience, Institute of Psychiatry, Denmark Hill, London, UK.
C C
CC
Miller
B H
BH
Anderton
D000544:Alzheimer Disease / Q000235:genetics* / Q000473:pathology* / Q000628:therapy*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics; D000818:Animals; D030801:Animals, Genetically Modified; D004195:Disease Models, Animal; D004314:Down Syndrome / Q000235:genetics; D006801:Humans
D016564:Amyloid beta-Protein Precursor